Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1030 • ACR Convergence 2022
Diagnostic Usefulness of Anti-PPM1A-IgM in Patients with Ankylosing Spondylitis
Yeo jin lee¹, Eun-Ju Lee², Soo Min Ahn², Seokchan Hong², Ji Seon Oh³, Chang Keun Lee², Bin Yoo² and Yong Gil Kim², ¹Asan medical center, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ³Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) has been known to have auto-inflammatory nature, hence, the efficacy of autoantibodies is low. However, studies on autoantibodies are ongoing, with…
Abstract Number: 1425 • ACR Convergence 2022
Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases
Ran Jin¹, Silvia Kruppert², Florian Scholz², Marc Hammer², Greg Kricorian¹, David Collier³ and Jonathan Kay⁴, ¹Amgen, Inc., Thousand Oaks, CA, ²IQVIA, Frankfurt, Germany, ³Amgen Inc., Simi Valley, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: ABP 501 is the first adalimumab (ADA) biosimilar approved by the European Medical Association and the Food and Drug Administration for the treatment of…
Abstract Number: PP07 • ACR Convergence 2022
Remissions and Vigilance
Michael Scepaniak, Cockeysville, MD
Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…
Abstract Number: 0399 • ACR Convergence 2022
ASAS Recommendations for Requesting and Reporting Imaging in Patients with Suspected Axial Spondyloarthritis
Torsten Diekhoff¹, Iris Eshed², Chiara Giraudo³, Hildrun Haibel⁴, Kay-Geert Hermann⁵, Manouk de Hooge⁶, Lennart Jans⁷, Anne Jurik⁸, Robert G Lambert⁹, Pedro Machado¹⁰, Walter P Maksymowych¹¹, Michael Mallinson¹², Helena Marzo-Ortega¹³, Victoria Navarro-Compán¹⁴, Susanne Pedersen¹⁵, Mikkel Østergaard¹⁶, Monique Reijnierse¹⁷, Martin Rudwaleit¹⁸, Fernando Andres Sommerfleck¹⁹, Ulrich Weber²⁰, Xenofon Baraliakos²¹ and Denis Poddubnyy²², ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Sheba Medical Center, Tel Aviv, Israel, ³University of Padova, Padova, Italy, ⁴Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁵Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Ghent University Hospital, Luxembourg, Luxembourg, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Aarhus University Hospital, Aarhus, Denmark, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰University College London, London, United Kingdom, ¹¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ¹²ASIF Axial Spondyloarthritis International Federation, London, United Kingdom, ¹³Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ¹⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ¹⁵Rigshospitalet, København, Denmark, ¹⁶Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ¹⁷Leiden University Medical Center, Leiden, Netherlands, ¹⁸University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ¹⁹Sanatorio Julio Mendez, Buenos Aires, Argentina, ²⁰Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ²¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Clinicians face uncertainties in their daily practice when requesting imaging for patients with suspicion of axial spondyloarthritis (axSpA) or producing a report because requirements…
Abstract Number: 0424 • ACR Convergence 2022
The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort
Sadettin Uslu¹, Semih Gulle¹, Gercek Can², Soner Senel³, Sedat Capar⁴, Huseyin ediz dalkilic⁵, Servet Akar⁶, Suleyman Serdar Koca⁷, Abdurrahman Tufan⁸, Ayten Yazici⁹, Sema Yilmaz¹⁰, Nevsun Inanc¹¹, Merih Birlik¹, Dilek Solmaz¹², Ayse Cefle⁹, Berna Goker¹³, Servet Yolbas¹⁴, Niels Steen Krough¹⁵, Neslihan Yilmaz¹⁶, Sukran Erten¹⁷, Cemal Bes¹⁸, Ozgul Soysal¹⁹, Mehmet Akif Ozturk¹³, Seminur Haznedaroglu¹³, Sule Yavuz¹⁶, Haner Direskeneli²⁰, Fatoş Onen²¹ and Ismail Sari²², ¹Dokuz Eylul University School of Medicine Division of Rheumatology, Izmir, Turkey, ²Dokuz Eylul University School of Medicine Division of Rheumatology, Istanbul, Turkey, ³Erciyes University School of Medicine Division of Rheumatology, Kayseri, Turkey, ⁴Dokuz Eylul University Faculty of Science Department of Statistics, Izmir, Turkey, ⁵Uludag University School of Medicine Division of Rheumatology, Bursa, Turkey, ⁶Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁷Firat University School of Medicine Division of Rheumatology, Elazıg, Turkey, ⁸Gazi University Medical Faculty Hospital, Istanbul, Turkey, ⁹Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, ¹⁰Selcuk University School of Medicine Division of Rheumatology, Konya, Turkey, ¹¹Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, ¹²Kâtip Celebi University School of Medicine Division of Rheumatology, Izmir, Turkey, ¹³Gazi University School of Medicine Division of Rheumatology, Ankara, Turkey, ¹⁴Inonu University School of Medicine Division of Rheumatology, Malatya, Turkey, ¹⁵Zitelab Aps, Kopenhag, Denmark, ¹⁶Demiroglu Bilim University School of Medicine Division of Rheumatology, Istanbul, Turkey, ¹⁷Yildirim Beyazit University School of Medicine Division of Rheumatology, Ankara, Turkey, ¹⁸Basaksehir Cam and Sakura ospital, Division of Rheumatology, Istanbul, Turkey, ¹⁹Celal Bayar University, School of Medicine Division of Rheumatology, Manisa, Turkey, ²⁰Marmara University School of Medicine Division of Rheumatology, Istanbul, Turkey, ²¹Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, ²²Dokuz Eylul University School of Medicine Division of Rheumatology, İzmir, Turkey
Background/Purpose: In this study, it was aimed to evaluate the long-term drug survival, efficacy and safety of infliximab biosimilar CT-P13 in Turkish patients diagnosed with…
Abstract Number: 1034 • ACR Convergence 2022
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
Kathryn Starzyk, Pam Kumparatana and roger Meng, OM¹, Inc., Boston, MA
Background/Purpose: Axial spondyloarthritis [AxSpA and particularly non-radiographic (nr)AxSpA] has one of the longest diagnostic delays in rheumatology. Although improving, lack of radiographic evidence of disease…
Abstract Number: 1426 • ACR Convergence 2022
Year-two Follow-up Results of an Observational Study Conducted in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Patients Treated with Infliximab Biosimilar CT-P13 in a Real-life Setting
Bruno Fautrel¹, Maryse Assing², Nadir Mammar², Yves Brault² and Hubert Marotte³, ¹Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ²Pfizer, Paris, France, ³INSERM 1059, Saint-Etienne, France
Background/Purpose: ReFLECT study has been carried out to investigate real life use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) originator.Methods: ReFLECT is…
Abstract Number: PP11 • ACR Convergence 2022
Exercise as a Supportive Treatment for My Ankylosing Spondylitis
Sara King-Dowling, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are often caught in a paradox as they experience mobility challenges, but long periods of immobility cause increased…
Abstract Number: 0402 • ACR Convergence 2022
Opioid Use and Healthcare Utilization in Adults with PsA and AS
Alexis Ogdie¹, Sofia Pedro², Jean Liew³ and Kaleb Michaud⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Boston University, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Opioid use among individuals with spondyloarthritis is common, reported to be ~20-30% in some cohorts. Data on whether this subset of patients have higher…
Abstract Number: 0425 • ACR Convergence 2022
Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
Sumit Bhatnagar¹, Doerthe Eckert², Sven Stodtmann², In-Ho Song³, Peter Wung³, Wei Liu³ and Mohamed-Eslam Mohamed³, ¹AbbVie, Highland Park, IL, ²AbbVie, Ludwigshafen, Germany, ³AbbVie, Inc., North Chicago, IL
Background/Purpose: The efficacy and safety profile of 15 mg once-daily (QD) upadacitinib (UPA), an oral, reversible, JAK inhibitor has been established in axial spondyloarthritis (axSpA),…
Abstract Number: 1036 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking
Alexis Ogdie¹, Lars Erik Kristensen², Enrique R Soriano³, Servet Akar⁴, Yanhui Sun⁵, David Gruben⁶, Lara Fallon⁷, Cassandra D Kinch⁸ and Dafna Gladman⁹, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, ³Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁵Pfizer CRDC, Shanghai, China, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Montréal, QC, Canada, ⁸Pfizer Canada ULC, Kirkland, Canada, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: In patients (pts) with PsA and AS, smoking may be associated with an increased comorbidity burden, and greater responses to TNF inhibitors (TNFi) are…
Abstract Number: 1489 • ACR Convergence 2022
Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis
Devy Zisman¹, Noa Hayat¹, Amir Haddad², Joy Feld³, Tal Gazitt¹, Idit Lavi¹, Ilan feldhamer⁴, ARNON DOV COHEN⁴ and Walid Saliba¹, ¹Carmel Medical Center, Haifa, Israel, ²Carmel Medical Centre, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Clalit Health Services, Tel Aviv, Israel
Background/Purpose: The importance and efficacy of anti COVID-19 vaccine in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: 0014 • ACR Convergence 2022
The Expanded CD21 Low B Cell Subpopulation in Ankylosing Spondylitis Consists Mainly of Antigen-Inexperienced Cells
Rick Wilbrink¹, Linda van der Weele², Anneke Spoorenberg¹, Niek De Vries², Frans Kroese¹ and Gwenny Verstappen¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University Medical Center Amsterdam, Amsterdam, Netherlands
Background/Purpose: The role of B cells in the pathogenesis of ankylosing spondylitis (AS) remains relatively understudied. Nevertheless, available evidence shows presence of B cells at…
Abstract Number: 0403 • ACR Convergence 2022
Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
Yu Xue¹, Jiankang Hu², Dongzhou Liu³, Jingyang Li⁴, Huaxiang Wu⁵, Chunyu Tan⁶, Lie Dai⁷, Mengru Liu⁸, Hongying Li⁸ and Hejian Zou¹, ¹Huashan Hospital affiliated to Fudan University, Shanghai, China, ²Jiangxi Pingxiang People’s Hospital, Shanghai, China, ³Shenzhen People’s Hospital （The Second Clinical Medical College of Jinan University）, Shanghai, China, ⁴Zhuzhou Central Hospital, Shanghai, China, ⁵The Second Affiliated Hospital Zhejiang University School of Medicine, Shanghai, China, ⁶West China Hospital of Sichuan University, Shanghai, China, ⁷Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Shanghai, China, ⁸Eli Lilly and Company, Shanghai, China
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in global clinical trials in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].